![](https://www.diabetesnews.com/wp-content/uploads/2014/02/FDA-Logo-150x150.jpg)
The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week.
Read more
The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week.
Read more